Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800718 | 1.00 | GAA (0.52) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL2801323 | 0.80 | GAA (0.60) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL2789687 | 0.80 | GAA (0.68) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL14417207 | 0.74 | CYP2D6 (0.55) | ALDH1A1KMT2APKMHPGDCYP2D6 | |
| SCHEMBL4709087 | 0.72 | MEN1 (0.84) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL8692307 | 0.72 | CYP2D6 (0.56) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL9919129 | 0.71 | SCN2A (0.49) | GAAALDH1A1KMT2AMEN1PKM | |
| SCHEMBL11184467 | 0.71 | TAS2R38 (0.50) | GAAALDH1A1KMT2AMEN1CYP2D6 | |
| SCHEMBL28683479 | 0.70 | MEN1 (0.51) | GAAALDH1A1KMT2AMEN1CYP2D6 | |
| SCHEMBL30116902 | 0.69 | NPC1 (0.53) | GAAALDH1A1KMT2APKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | GAA 932/4885ALDH1A1 1066/4885KMT2A 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.